Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
about
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisMesalamine in the treatment and maintenance of remission of ulcerative colitis2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center TrialCurrent approaches to the management of new-onset ulcerative colitis.Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study.New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence5-ASA Dose-Response: Maximizing Efficacy and Adherence.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.Current and emerging drugs for the treatment of inflammatory bowel disease.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisSecond Korean guidelines for the management of ulcerative colitis.Review article: remission rates achievable by current therapies for inflammatory bowel disease.Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.Mucosal healing in Crohn's disease: a systematic review.Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.Ulcerative colitis: prevention of relapse.Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.Drug Management in the Elderly IBD Patient.Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.High Dietary Intake of Specific Fatty Acids Increases Risk of Flares in Patients With Ulcerative Colitis in Remission During Treatment With Aminosalicylates.Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel diseaseOptimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence.Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.Once-daily mesalamine granules for ulcerative colitis.Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.Adalimumab for the treatment of inflammatory bowel disease.The use of the Medication Event Monitoring System (MEMS) for assessing medication adherence for chronic conditions: use and results from a 12 month trial of patients in remission with ulcerative colitis (UC).
P2860
Q24185774-21189BBE-57A0-45D6-A413-36AA06DCFDEEQ24198786-8D969E18-659D-4E01-AEBB-CE881F63FA09Q26865546-56922974-05C9-4657-BD01-F59670BCD19BQ33601419-A2C9BF3C-C98A-4EB2-8D2A-B7B6CA233857Q33633288-00DEEA58-4416-498E-8AFF-222EF1737E1EQ33819506-E2BD2BAA-192A-4B3F-86DC-6400264B7B48Q33916287-D6C91A46-645C-4654-BE0C-06120FE6BF93Q33916329-85AC6850-DB47-48A4-9A5D-7666AD4F95D2Q34273329-A19C495A-DDE7-4FDB-9F1F-5F195EBBFD06Q34567518-98BA387F-9FEA-475F-9A4F-E2C41DE227B9Q34883210-4AA6A59E-388C-4277-99F5-FBA9D7E2480DQ36144377-47F8F484-51F7-4108-B5AC-378664EA56A8Q36172156-9E009D91-D13F-4567-B6D2-CE129E929A1BQ37101734-176FF077-DBE7-46EC-BB8F-BC07E3450676Q37662503-DBD913BC-BBD1-4AB1-8088-F72F76CA4B85Q37842605-BC5AB1ED-231A-43A5-BE71-C7A3B1BDEB35Q37926915-9C58E4E2-6D1F-438C-A5E1-549BB9901562Q37995669-3909D75D-E691-4222-8E1A-F0E737286027Q38005972-0CCB3916-FB09-4332-86DA-606E87FFF269Q38014364-54FC7790-0615-45F5-B4FC-E5B164AD60C1Q38103628-099431CE-B7DC-459D-ACEF-6DF5CC4B1E48Q38109019-35938CB4-C10A-476E-9486-710DFDE5CF0DQ38330651-4CABC41F-258A-4A7D-83CF-110D5733E497Q38396153-E997EE6B-071C-4667-AE05-EE0478DB5936Q38471121-38EDD1E9-5B02-4583-AF55-2F7206D92937Q38625992-370D5E70-502D-49C4-AAF7-6B6C0CB952CDQ38841927-42C13001-1E99-476D-A567-D3766CD6D0C7Q39007572-015E99F3-A9E5-415B-9CD2-091CE264210FQ40926333-F0653922-7D70-4F08-A47A-51281F43C4B3Q41891210-2EDE758E-FEA3-43D5-972F-7991601A451BQ42273744-2CC402A6-CAAE-404F-96E7-C5E6AE1D3B10Q42877648-9BEEA6FF-9797-46A5-9C5D-8A4C001FEC2AQ42995730-F7B133B4-75A8-410B-A04C-07FA79FF55AEQ43834227-63829AC7-EF10-48D1-98C4-2785D1A28B16Q45295209-01FE9E88-B280-4539-9873-38EE400C6593Q46670774-69E7A6FA-6EB6-4210-A51E-15E8A351DB44Q46742896-A0D44354-4BC9-48CF-991B-A04878363DBA
P2860
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Once-daily dosing of delayed-r ...... mission of ulcerative colitis.
@en
Once-daily dosing of delayed-release oral mesalamine
@nl
type
label
Once-daily dosing of delayed-r ...... mission of ulcerative colitis.
@en
Once-daily dosing of delayed-release oral mesalamine
@nl
prefLabel
Once-daily dosing of delayed-r ...... mission of ulcerative colitis.
@en
Once-daily dosing of delayed-release oral mesalamine
@nl
P2093
P1433
P1476
Once-daily dosing of delayed-r ...... mission of ulcerative colitis.
@en
P2093
Bret Lashner
Charles A Sninsky
David Ramsey
James F Marion
Jonathan A Leighton
Joshua Korzenik
Keith A Friedenberg
Michael Safdi
Preston Dunnmon
Raman M Patel
P304
1286-96, 1296.e1-3
P356
10.1053/J.GASTRO.2009.12.054
P407
P577
2010-01-11T00:00:00Z